Published in Cancer Lett on May 01, 1980
Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival. Br J Cancer (1980) 1.38
Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation. Br J Cancer (1981) 1.15
Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. Br J Cancer (1982) 0.96
Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain. Br J Cancer (1982) 0.91
The response of tumour cells to radiation and cytotoxic drugs--a comparison of clonogenic and isotope uptake assays. Br J Cancer (1984) 0.83
Improved assay of stromal injury based on the number of tumour cells that can be supported by irradiated flank skin. Br J Cancer Suppl (1986) 0.75
A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst (1980) 3.75
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
A simplified method for production and growth of multicellular tumor spheroids. Cancer Res (1977) 2.32
Studies of "potentially lethal damage" in EMT6 mouse tumour cells treated with bleomycin either in vitro or in vivo. Br J Cancer (1975) 2.02
The sensitivity to bleomycin of a solid mouse tumour at different stages of growth. Br J Cancer (1974) 1.88
Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer (1986) 1.66
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer (1990) 1.59
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. Int J Radiat Oncol Biol Phys (1979) 1.49
Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res (1980) 1.42
Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer (1987) 1.40
Autogenous immunity to endogenous RNA tumor virus antigens in mice with a low natural incidence of lymphoma. Cancer Res (1972) 1.39
A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst (1994) 1.39
Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. Br J Cancer (1981) 1.38
Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival. Br J Cancer (1980) 1.38
Sensitivity to cytotoxic agents of the EMT6 tumour in vivo: tumour volume versus in vitro plating. 1. Cyclophosphamide. Br J Cancer (1977) 1.36
Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer (1993) 1.34
Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer (1995) 1.32
Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy. Radiat Res (1977) 1.31
Predictive chemosensitivity testing. Br J Cancer (1985) 1.30
The response to cytotoxic drugs of EMT6 cells treated either as intact or disaggregated spheroids. Br J Cancer (1985) 1.28
Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep (1979) 1.28
Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer (1993) 1.18
Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst (1969) 1.18
The MTT assay underestimates the growth inhibitory effects of interferons. Br J Cancer (1989) 1.16
The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials (1980) 1.15
Timing of assays: an important consideration in the determination of clonogenic cell survival both in vitro and in vivo. Int J Radiat Oncol Biol Phys (1979) 1.15
Drug resistance in human lung cancer cell lines: cross-resistance studies and effects of the calcium transport blocker, verapamil. Int J Radiat Oncol Biol Phys (1986) 1.15
Changes in cell proliferation kinetics occurring during the life history of monolayer cultures of a mouse tumour cell line. Cell Tissue Kinet (1975) 1.14
Liquid-overlay culture of cellular spheroids. Recent Results Cancer Res (1984) 1.14
The sensitivity of cells in exponential and stationary phases of growth to bleomycin and to 1,3-bis(2-chloroethyl)-1-nitrosourea. Br J Cancer (1973) 1.13
The sensitivity to cytotoxic agents of the EMT6 tumor in vivo. Comparative response of lung nodules in rapid expotential growth and of the solid flank tumour. Br J Cancer (1976) 1.12
Comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro model systems. Cancer Treat Rep (1976) 1.12
An artefact in clonogenic assays of bleomycin cytotoxicity. Br J Cancer (1977) 1.11
Misonidazole enhancement of acute and late radiation injury to the rat spinal cord. Br J Cancer (1979) 1.11
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. Br J Cancer (1983) 1.11
Growth delay in small EMT6 spheroids induced by cytotoxic drugs and its modification by misonidazole pretreatment under hypoxic conditions. Br J Cancer (1982) 1.11
Changes in sensitivity to cytotoxic agents occurring during the life history of monolayer cultures of a mouse tumour cell line. Br J Cancer (1975) 1.09
Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism. Biochem Pharmacol (1983) 1.06
Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer (1991) 1.06
On mouse strain differences in radiation resistance: hematopoietic death and the endogenous colony-forming unit. Radiat Res (1969) 1.06
Growth fraction as the major determinant of multicellular tumor spheroid growth rates. Cancer Res (1978) 1.04
The sensitivity to bleomycin of spleen colony forming units in the mouse. Br J Cancer (1973) 1.04
Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur J Cancer (1994) 1.04
Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep (1980) 1.04
In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo. Cancer Res (1978) 1.04
Chemoprotection against three modes of radiation death in the mouse. Int J Radiat Biol Relat Stud Phys Chem Med (1969) 1.03
Development of concomitant immunity in mice bearing the weakly immunogenic line 1 lung carcinoma. Cancer Res (1975) 1.03
Response to the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. J Natl Cancer Inst (1980) 1.03
Experimental chemotherapy studies: intercomparison of assays. Br J Cancer Suppl (1980) 1.02
Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships. Int J Radiat Oncol Biol Phys (1982) 1.01
Cloning of human lung cancer cells. Br J Cancer (1985) 1.01
A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor. Cancer Res (1974) 1.00
Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. Br J Cancer (1982) 0.98
Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line. Br J Cancer (1990) 0.97
Neuraminidase and cell viability: failure to detect cytotoxic effects with dye-exclusion techniques. J Natl Cancer Inst (1974) 0.96
The effect of bleomycin and radiation in combination on bacteria and mammalian cells in culture. Br J Radiol (1974) 0.96
Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer (1998) 0.96
Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. Br J Cancer (1989) 0.95
Multicellular tumor spheroid formation by breast cancer cells isolated from different sites. Cancer Res (1978) 0.95
Separation of clonogenic tumour cells from EMT6 mouse mammary tumours. Br J Cancer (1977) 0.95
Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol (1989) 0.94
Exposure-response curve for radiation-induced lung tumors in the mouse. Radiat Res (1973) 0.94
Preclinical pharmacokinetics of benznidazole. Br J Cancer (1984) 0.93
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. Genomics (1991) 0.93
Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. Cancer Res (1974) 0.93
The response of EMT6 tumor spheroids to combined treatment with misonidazole and either nitrogen mustard, adriamycin, or BCNU. Cancer Clin Trials (1980) 0.92
The relationship between tumour geometry and the response of tumour cells to cytotoxic drugs--an in vitro study using EMT6 multicellular spheroids. Int J Cancer (1985) 0.92
Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol (1989) 0.92
Radiotherapy of experimental lung tumors in the presence and absence of a radioprotective drug, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). J Natl Cancer Inst (1973) 0.92
Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer (1988) 0.92
Heritability of plasma cholinesterase activity in inbred mouse strains. Science (1967) 0.92
Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer (1980) 0.91
Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer (1995) 0.91
Bleomycin--mode of action with particular reference to the cell cycle. Pharmacol Ther (1983) 0.91
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int J Cancer (1995) 0.90
Pro-opiomelanocortin gene expression and peptide secretion in human small-cell lung cancer cell lines. J Mol Endocrinol (1989) 0.90
Inhibition of murine RNA tumor virus replication and oncogenesis by chloroquine. Int J Cancer (1974) 0.90
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol (1996) 0.90
Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys (1984) 0.89
The effect of cytotoxic drugs with or without misonidazole on leucopenia in three strains of mice. Int J Radiat Oncol Biol Phys (1982) 0.88
Collateral resistance to verapamil in multidrug-resistant mouse tumor cells. J Natl Cancer Inst (1989) 0.87
The in vitro effects and cross-resistance patterns of some novel anthracyclines. Br J Cancer (1986) 0.86
Neuron specific enolase expression in carcinoma of the lung. Br J Cancer (1986) 0.86
Protective drugs in cancer therapy: optimal clinical testing and future directions. Int J Radiat Oncol Biol Phys (1982) 0.85
Use of a tritiated thymidine suicide technique in the study of the cytotoxic drug response of cells located at different depths within multicellular spheroids. Br J Cancer (1987) 0.85
A more general role for WR-2721 in cancer therapy. Br J Cancer (1980) 0.85
Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses. Radiat Res (1970) 0.85
The effects of alpha and gamma interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. Br J Cancer (1985) 0.85
Senescent loss of resistance to murine sarcoma virus (Moloney) in the mouse. Cancer Res (1973) 0.85
The effects of repeated doses of bacterial endotoxin on erythropoiesis in the normal and splenectomized mouse. Br J Haematol (1972) 0.84
Chemosensitization by lipophilic nitroimidazoles. Br J Cancer (1983) 0.84
Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies. Br J Cancer (1992) 0.83
Phase I clinical studies with WR-2721. Cancer Clin Trials (1980) 0.83
Action of cytotoxic agents on the erythroid system of the mouse. J Natl Cancer Inst (1970) 0.83
Ploidy distribution of tumour cells derived from induced and spontaneously arising metastases of a murine radiation-induced sarcoma, RIF-1. Eur J Cancer Clin Oncol (1982) 0.83
The response of tumour cells to radiation and cytotoxic drugs--a comparison of clonogenic and isotope uptake assays. Br J Cancer (1984) 0.83
Oncogene amplification and chromosomal abnormalities in small cell lung cancer. J Cell Biochem (1987) 0.83
Response to X-radiation and cytotoxic drugs of clonal subpopulations of different ploidy and metastatic potential isolated from RIF-1 mouse sarcoma. Br J Cancer (1983) 0.83